Seeking Alpha HealthcareOriginal article
Praxis signals two FDA decisions in ~six months, targets ~$10B ulixacaltamide peak sales while building a ~300-person field force
RegulatoryulixacaltamidePositive
AI Analysis
Summary
Praxis signals two FDA decisions expected within approximately six months and targets ~$10B peak sales for ulixacaltamide while building a ~300-person field force.
Financial Highlights
Guidance
~$10B ulixacaltamide peak sales target
Outcome Details
Two FDA decisions expected within approximately six months
Importance:6/10
Sentiment:
0.50
FDAregulatorypeak sales guidancefield force expansion
Related Companies
Read the original article
Published by Seeking Alpha Healthcare on August 7, 2026 12:27 PM